UBS reiterates its 'buy' recommendation on the stock, but lowers its target price to 7500 pence (from 7640 pence), which represents a potential upside of 27%.

'We believe that the stock's recent pullback offers an attractive entry point into CRH. We expect forecasts to be maintained, as are results' says UBS.

CRH has confirmed its full-year adjusted Ebitda target of between $6.55 and $6.85 billion.

The group, which has completed a $2.1 billion acquisition in the Texas cement business, says it has identified potential synergies of $60 million on an annualized basis from the deal.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.